Marketing Funding Sample Clauses

Marketing Funding. 47 5.3 Implementation of U.S. Marketing Plans ................................... 48 5.4
AutoNDA by SimpleDocs
Marketing Funding. 5.2.1 Adolor Products in the United States. Subject to reconciliation ------------------------------------ as provided in Section 6.7.5, on an Adolor Product-by-Adolor Product basis, Adolor shall be responsible and pay for ** percent (**%) and GSK shall be responsible and pay for ** percent (**%) of the Marketing Expenses for each Adolor Product for Commercialization in the United States incurred from ** through the First Commercial Sale for such Adolor Product. Thereafter, Marketing Expenses for each Adolor Product shall be shared in accordance with the sharing of the Adolor Product Marketing Contribution for such Adolor Product as adjusted pursuant to Section 6.3.4. Notwithstanding the foregoing, if a ** Study for an Adolor Product is not commenced earlier than ** (**) years prior to the expiration of the Adolor Product Promotion Term and such ** Study has no applicability to a Collaboration Product in any Country in the ROW, Adolor shall be responsible and pay for ** (**%) of any such ** Study.
Marketing Funding. OneSoft will allocate co-marketing funds focused on USWeb/CKS iAMcommerce Solutions Powered by OneSoft to be used as agreed upon by both parties in the Marketing and PR Plan, as follows: 1999 - $***, 2000 - $***, 2001 - $***; USWeb/CKS will allocate marketing funds focused on USWeb/CKS iAMcommerce Solutions Powered by OneSoft, to be used as agreed upon by both parties in the Marketing and PR Plan, as follows: 1999 - $***, 2000 - $***, 2001 - $***. OneSoft and USWeb/CKS agree to give reasonable consideration to proposals for providing additional joint marketing funds for events or activities sponsored by OneSoft or USWeb/CKS beyond the foregoing minimum commitments; contribution ratios for these additional funds will be as mutually agreed on a case-by-case basis. The parties will expend funds for approved marketing activities in accordance with the Marketing and PR Plan and will exchange annual expenditure reports. Amounts remaining in a given year will be carried over to the next year (and will be settled as payment in kind or cash at the end of the initial term of the Agreement) or upon termination of this Agreement if earlier.

Related to Marketing Funding

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Development Funding (a) Viewray will pay 3D Line the then U.S. Dollar equivalent of €[***] within three (3) days of the Effective Date for the engineering services required to develop/ deliver the Deliverable described in Section 2.1(a)(i).

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Marketing Services The Manager shall provide advice and assistance in the marketing of the Vessels, including the identification of potential customers, identification of Vessels available for charter opportunities and preparation of bids.

  • Residential Funding Residential Funding Corporation, a Delaware corporation, in its capacity as seller of the Mortgage Loans to the Company and any successor thereto.

  • REMIC Administrator: Residential Funding Corporation If Residential Funding Corporation is found by a court of competent jurisdiction to no longer be able to fulfill its obligations as REMIC Administrator under this Agreement the Master Servicer or Trustee acting as Master Servicer shall appoint a successor REMIC Administrator, subject to assumption of the REMIC Administrator obligations under this Agreement.

  • Development Services Licensee may from time to time wish to augment the RMSS product with additional functionality or utility, or to integrate it with Licensee systems from other sources, and for such purposes may request the provision of development services from RMSS.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Initial Funding The obligation of the Lenders to make the Initial Funding is subject to the receipt by the Agent and the Lenders of all fees payable pursuant to Section 2.04 on or before the Closing Date and the receipt by the Agent of the following documents and satisfaction of the other conditions provided in this Section 6.01, each of which shall be satisfactory to the Agent in form and substance:

  • Sales and Marketing Subdistributor shall market, promote, and solicit orders for the Products to prospective and existing Customers (excluding the Excluded Customers) consistent with good business practice and the highest professional standards in the industry, in each case using its best efforts to maximize Product sales volume in the Territory in accordance with Distributor’s Product marketing strategies, channel and pricing guidelines, and sales policies, and in a manner that reflects favorably at all times on the Products and the good name, goodwill, and reputation of Distributor;

Time is Money Join Law Insider Premium to draft better contracts faster.